Sight sciences CEO Paul Badawi sells shares value $72,570

Paul Badawi, the President and CEO of Sight Sciences , Inc. (NASDAQ:SGHT), reported a sale of 24,819 shares of the corporate’s frequent inventory. The transaction, which befell on January 16, 2025, was executed at a weighted common worth of $2.924 per share, leading to a complete worth of roughly $72,570. The sale comes amid difficult market situations for SGHT, with the inventory down over 63% previously six months and at the moment buying and selling close to its 52-week low of $2.67. Following this sale, Badawi retains possession of 5,676,331 shares immediately. The shares have been offered to cowl tax liabilities related to the vesting of restricted inventory items. Whereas InvestingPro evaluation signifies the corporate maintains robust liquidity with a present ratio of 10.18 and holds more money than debt, the inventory seems undervalued based on InvestingPro’s Truthful Worth mannequin. Traders can entry detailed evaluation and 10 further key insights about SGHT by means of InvestingPro’s complete analysis report.

In different latest information, Sight Sciences Inc. has been going through changes and predictions from varied monetary companies. Lake Avenue Capital Markets has revised Sight Sciences’ worth goal from $5.00 to $3.00, sustaining a Maintain ranking on the corporate’s shares. This adjustment follows latest adjustments in Medicare protection, affecting the business and Sight Sciences’ market share. Regardless of these challenges, the corporate is actively managing its funds to keep up liquidity.

Sight Sciences has additionally projected modest income development in This fall 2024, pushed by surgical glaucoma product gross sales. The corporate’s preliminary monetary outcomes for the fourth quarter and full yr of 2024 point out a slight improve in whole income for the quarter, whereas annual income is anticipated to say no by 2% in comparison with 2023. Nonetheless, surgical glaucoma revenues are anticipated to develop by 2%.

A latest research confirmed the effectiveness of Sight Sciences’ OMNI Surgical System in decreasing intraocular stress in sufferers with main open-angle glaucoma. Moreover, the corporate has secured a further $5 million in mortgage funding from its present credit score facility with Hercules Capital (NYSE:HTGC), Inc. and associates, elevating the whole borrowed quantity to $40 million.

UBS has initiated protection of Sight Sciences with a Purchase ranking, forecasting robust gross sales development by 2026. The UBS analyst expects the corporate’s TearCare Dry Eye answer to drive double-digit gross sales development and gross margin enlargement that exceeds consensus estimates for 2026 and past. These are latest developments in Sight Sciences’ operations and monetary efficiency.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.